New Report Assesses How Changes in Diagnosis Rates Will Influence the Type 2 Diabetes Market
Posted on: Tuesday, 5 February 2008, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c81818) has announced the addition of Datamonitor's new report: Stakeholder Insight: Diabetes to their offering.
Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established classes of oral anti-diabetic agents an unmet need for a safe, efficacious agent which can halt or reverse long-term disease progression remains.
Scope
- Survey of 180 PCPs, medical diabetologists and endocrinologists conducted in the seven major markets
- Comparison of physician survey with recent clinical developments, clinical trial results and current clinical guidelines
- Investigation of clinical unmet needs
Highlights of this title
Type 2 diabetes is an emerging epidemic with an estimated 55 million people affected by the condition in the seven major markets. Despite the raise profile of the disease physician research reveals that only approximately 50% of patients are diagnosed and of those around 80% receive treatment
Novel classes of incretin mimetics, GLP-1 agonist and DDP-IV inhibitors, have the potential to improve time to secondary failure and are likely to be adopted by international guidelines in the near future. Despite the launch of these new products significant unmet needs remain in drug efficacy, safety and disease progression.
Long-term safety data is expected to become increasingly important following safety issues raised by recent meta-analyses of rosiglitazone over ischemic events. This will raise the safety bar for new products and is likely to lead to new classes requiring a long safety record before they are recommended as 1st- or 2nd- line therapies
Key reasons to purchase this title
- Assess how changes in diagnosis rates will influence the type 2 diabetes market
- Identify the changes in physician prescription habits and the changes in complication rates and analyze the impact of changes in treatment decisions
- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Companies Mentioned:
Ajinomoto Co., Inc.
Alkermes Inc
Amylin Pharmaceuticals Inc
BP Plc
Bristol-Myers Squibb Company
CDC SPA
Central European Media Enterprises Ltd.
Eli Lilly and Company
Felix Resources Limited
GlaxoSmithKline Plc
Insight Communications Company, Inc.
Merck & Co., Inc.
Merck KGaA
Novartis AG
Novo Nordisk A/S
Pfizer Inc
For more information visit http://www.researchandmarkets.com/reports/c81818
Source: Business Wire
Related Articles
- Lab Group Recognizes the National Changing Diabetes Program for New Study on Quality Measures in Diabetes
- ApoCell and Reata Initiate Phase II Diabetic Renal Disease Trial
- Reata Pharmaceuticals Contracts ApoCell to Detect Innovative Biomarkers in a Phase II Clinical Study of RTA 402 for Diabetic Renal Disease
- Drug Therapy Benefits Diabetic Eye Disease
- Living Cell Technologies and US-Based Barbara Davis Center to Collaborate on Diabetes Clinical Trial Program
- MetaCure Initiates Diabetes Clinical Trial
- Novo Nordisk Changing Diabetes(SM) Bus World Tour Tackles Diabetes Epidemic in Chicago
- Speedel Stops Current SPP301 Phase III Trial in Diabetic Kidney Disease in the Interests of Patient Safety; Data to Be Analysed for Potential New Clinical Trials
- Diabetic Kidney Disease Linked to Obesity
- Hypertension and Diabetic Kidney Disease -- Commercial Performance of Both ACE Inhibitors and ARBS is Dependent on Renoprotective Benefits Beyond Blood Pressure Control
 |
 |
User Comments (0)
RSS Feeds